- Posts:
- 0 (0 per day)
- Age:
- N/A
- Date Registered:
- May 06, 2024, 03:55:28 PM
- Local Time:
- May 19, 2024, 11:01:37 AM
- Last Active:
- May 06, 2024, 06:19:54 PM
Signature:
4% acquired gadolinium-enhancing wounds. Median EDSS with Twelve months has been unchanged. Ocrelizumab efficiently governed relapse threat and handic